Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

China flag China · Delayed Price · Currency is CNY
43.35
-0.26 (-0.60%)
Sep 30, 2025, 3:00 PM CST
-0.60%
Market Cap28.87B
Revenue (ttm)5.99B
Net Income (ttm)3.50B
Shares Out770.09M
EPS (ttm)4.54
PE Ratio9.54
Forward PE40.14
Dividend1.28 (2.95%)
Ex-Dividend DateJul 4, 2025
Volume3,324,636
Average Volume7,048,096
Open43.61
Previous Close43.61
Day's Range43.22 - 43.82
52-Week Range28.53 - 50.97
Beta0.80
RSI44.99
Earnings DateOct 31, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ... [Read more]

Sector Healthcare
Founded 1981
Employees 4,619
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600329
Full Company Profile

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial Statements

News

There is no news available yet.